{"success":true,"data":{"pressRelease":{"id":"32371","rtpr_id":"nBw6dztkna","ticker":"DMAC","exchange":"NASDAQ","all_tickers":["DMAC"],"title":"DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference","author":"Business Wire","published_at":"2026-05-12T20:15:00.350Z","article_body":"DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global\nHealthcare Conference\n\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical\ncompany focused on developing novel treatments for preeclampsia, fetal growth\nrestriction and acute ischemic stroke, today announced that its President and\nCEO, Rick Pauls, will participate in a fireside chat at the upcoming 2026 RBC\nCapital Markets Global Healthcare Conference on Tuesday, May 19(th) in New\nYork City.\n\nFireside Chat Details\n\nDate & Time: Tuesday, May 19, 2026 | 4:05-4:30 PM ET\n\nLocation: InterContinental New York Barclay NY | 111 E 48(th) Street, New\nYork, NY 10017\n\nMr. Pauls will also be available for one-on-one meetings with investors during\nthe conference.\n\nAbout DiaMedica Therapeutics Inc.\n\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company\ncommitted to improving the lives of people suffering from serious ischemic\ndiseases with a focus on preeclampsia, fetal growth restriction and acute\nischemic stroke. DiaMedica’s lead candidate DM199 is the first\npharmaceutically active recombinant (synthetic) form of the KLK1 protein, an\nestablished therapeutic modality in Asia for the treatment of acute ischemic\nstroke, preeclampsia and other vascular diseases. For more information visit\nthe Company’s website at www.diamedica.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.diamedica.com&esheet=54534512&newsitemid=20260512758158&lan=en-US&anchor=www.diamedica.com&index=1&md5=09ea857d1d790aa5ce56962e568a643e)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260512758158/en/\n(https://www.businesswire.com/news/home/20260512758158/en/)\n\nScott Kellen\n\nChief Financial Officer\n\nPhone: (763) 496-5118\n\nskellen@diamedica.com (mailto:skellen@diamedica.com)\n\nFor Investor Inquiries: \n\nMike Moyer\n\nManaging Director, LifeSci Advisors, LLC\n\nPhone: (617) 308-4306\n\nmmoyer@lifesciadvisors.com (mailto:mmoyer@lifesciadvisors.com)\n\nMedia Contact: \n\nMadelin Hawtin\n\nLifeSci Communications\n\nmhawtin@lifescicomms.com (mailto:mhawtin@lifescicomms.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw6dztkna","title":"DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference","author":"Business Wire","ticker":"DMAC","created":"2026-05-12T20:15:00.350Z","tickers":["DMAC"],"exchange":"NASDAQ","article_body":"DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global\nHealthcare Conference\n\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical\ncompany focused on developing novel treatments for preeclampsia, fetal growth\nrestriction and acute ischemic stroke, today announced that its President and\nCEO, Rick Pauls, will participate in a fireside chat at the upcoming 2026 RBC\nCapital Markets Global Healthcare Conference on Tuesday, May 19(th) in New\nYork City.\n\nFireside Chat Details\n\nDate & Time: Tuesday, May 19, 2026 | 4:05-4:30 PM ET\n\nLocation: InterContinental New York Barclay NY | 111 E 48(th) Street, New\nYork, NY 10017\n\nMr. Pauls will also be available for one-on-one meetings with investors during\nthe conference.\n\nAbout DiaMedica Therapeutics Inc.\n\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company\ncommitted to improving the lives of people suffering from serious ischemic\ndiseases with a focus on preeclampsia, fetal growth restriction and acute\nischemic stroke. DiaMedica’s lead candidate DM199 is the first\npharmaceutically active recombinant (synthetic) form of the KLK1 protein, an\nestablished therapeutic modality in Asia for the treatment of acute ischemic\nstroke, preeclampsia and other vascular diseases. For more information visit\nthe Company’s website at www.diamedica.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.diamedica.com&esheet=54534512&newsitemid=20260512758158&lan=en-US&anchor=www.diamedica.com&index=1&md5=09ea857d1d790aa5ce56962e568a643e)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260512758158/en/\n(https://www.businesswire.com/news/home/20260512758158/en/)\n\nScott Kellen\n\nChief Financial Officer\n\nPhone: (763) 496-5118\n\nskellen@diamedica.com (mailto:skellen@diamedica.com)\n\nFor Investor Inquiries: \n\nMike Moyer\n\nManaging Director, LifeSci Advisors, LLC\n\nPhone: (617) 308-4306\n\nmmoyer@lifesciadvisors.com (mailto:mmoyer@lifesciadvisors.com)\n\nMedia Contact: \n\nMadelin Hawtin\n\nLifeSci Communications\n\nmhawtin@lifescicomms.com (mailto:mhawtin@lifescicomms.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-12T20:15:00.520173747Z","server_sent_at_ms":1778616900520},"received_at":"2026-05-12T20:15:00.688Z","source_url":"https://www.businesswire.com/news/home/20260512758158/en/"},"analysis":null,"durationMs":null,"modelName":null}}